This week in therapeutics




Licensing status

Publication and contact information


Breast cancer

(IL-6); interleukin-8
(IL-8; CXCL8)

Mouse and cell culture studies suggest dual blockade of IL-6 and IL-8 could be useful for treating triple-negative breast cancer. In a human triple-negative breast cancer cell line, small hairpin RNA-mediated knockdown of the two targets decreased anchorage-independent growth and increased apoptosis compared with knockdown of either interleukin alone. In a mouse xenograft model for triple-negative breast cancer, shRNA-mediated knockdown of both IL-6 and IL-8 inhibited tumor growth, whereas knockdown of either interleukin alone did not. Next steps could include developing and evaluating inhibitors of IL-6 and IL-8 signaling in models for triple-negative breast cancer.

SciBX 6(23); doi:10.1038/scibx.2013.571
Published online June 13, 2013

Patent and licensing status unavailable

Hartman, Z.C. et al. Cancer Res.; published online April 30, 2013;
Contact: Powel H. Brown, The University of Texas MD Anderson Cancer Center, Houston, Texas